leisure time -WSS

leisure time

author：knowledge 2025-10-02 01:07:46 - browse：98295

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

WSS

Male and female sex labels in research insufficient, scientists say

5 ways to address the shortage of health care workers

Pfizer is about to make a big push in cancer. Will investors listen?

NEJM study measures Covid brain fog, impact on IQ

Ebola: Gilead Sciences antiviral shows promise as new treatment

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

explore

leisure time

focus

Novavax promises a turnaround & Lilly roils the obesity market

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Medical records are filled with copy

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Peter Hotez and the public health issue of online harassment

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

State Dept. review finds Biden bears some blame for Afghanistan failures

Childhood vaccination ad campaign launches in the U.K.

focus

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Neuroscience renaissance leads to new crop of psychiatric drugs

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

WuXi out of biotech trade group, U.S. and China relations to blame

leisure time

hotspot

focus

knowledge